Adhesives Research Breaks Ground on New Pharmaceutical Manufacturing Facility
AR and Novartis Partner to Bring Active Thin Films to Consumers
GLEN ROCK, Pa. (May 19, 2006) - On Friday, April 21, 2006, the ARx(TM) division of Adhesives Research, Inc., broke ground on a new 25,000 square-foot facility to manufacture active pharmaceutical products. The addition of this new stand-alone facility will further expand the company's manufacturing capacity and laboratory space to support a rapidly growing portfolio of projects and clients. ARx(TM) is a client-focused, custom developer and supplier of high-quality drug and biopharmaceutical delivery materials and technologies for the pharmaceutical industry. The new plant will bring the total square footage on the AR campus to more than 240,000 square feet -with 38,000 square feet dedicated to ARx(TM).
Also at the groundbreaking ceremony, Novartis Consumer Health (NCH) discussed its ongoing partnership with Adhesives Research. Since 2003, Adhesives Research has been the exclusive developer and supplier of active dissolvable films for NCH's Triaminic® Thin Strips(TM) pediatric cough and cold products and Theraflu® Thin Strips(TM) cold and flu products. The ARx(TM) Division currently supports six commercial dissolvable film products and expects to launch an additional twenty new products over the next three years.
"We are excited about breaking ground on a new facility for the production of active pharmaceutical products," said ARx(TM) Vice President and General Manager Beth Vondrak. "The successful commercialization of NCH's Triaminic® and Theraflu® Thin Strips(TM) products is just the beginning of a relationship that will benefit from this new state-of-the-art facility."
Dissolvable thin strip technology provides consumers with a new format for taking over-the-counter and prescription medicines. Key benefits of the technology include fast, accurate dosing as well as portability and convenience. The strips are a viable alternative to traditional medicines, especially for populations who have trouble swallowing pills. "Together, Novartis and AR are the market leaders in this technology," said Kären Olson, President and CEO of Adhesives Research.
"In the future, global markets will be reached while developing thin strips for many different therapeutic categories, enhancing our position as leaders in this technology," added Carlos Ceinos, Site Manager of NCH/Ex-Lax in Puerto Rico. "Together, we are turning vision into action to make the thin strip technology the premier drug delivery system."
About Adhesives Research
Founded in 1961, Adhesives Research offers problem-solving capabilities and custom solutions in adhesive polymerization, mixing, adhesive coating, and release liner design supported by extensive product development and analytical support. Adhesives Research's products are used around the world in medical diagnostics and devices, wound care, pharmaceuticals/transdermals, and consumer products as well as the electronics, automotive, display, window fabrication, and pulp and paper industries.
Based in Glen Rock, Pennsylvania, Adhesives Research also operates manufacturing facilities in Ireland, Australia, and Colombia, has sales and marketing offices in Great Britain, Germany, and Singapore, and sales representation in Japan, Korea, Taiwan, and Thailand. The Company's North American and Limerick, Ireland, facilities are certified to the updated ISO 9001:2000 standard. For more information, please visit www.adhesivesresearch.com.
About Novartis Consumer Health
Novartis Consumer Health OTC (Over-The-Counter) is a world leader in the development, production, and marketing of self-medication products for the in-home treatment and prevention of medical conditions and ailments and to enhance overall health and well being. Novartis has leading brand positions in a number of important category segments, most notably in topical analgesics, athlete's foot and nasal decongestants. The main product categories are cough, cold, allergy, gastrointestinal, dermatological and smoking cessation treatments, as well as mineral supplements. For more information, please visit novartis.com/consumerhealth.
Contact: Andrea Jackson
(800) 445-6240, ext. 3309
Email: ajackson@arglobal.com
Web: www.adhesivesresearch.com/
